Accurate knowledge of heat transfer to materials in recombining plasmas is needed to improve heat shield designs. A lack of understanding of the chemical component of surface heating motivates the use of conservative assumptions with regards to surface catalysis in the design of thermal protection systems (TPS) that detrimentally impact payload capability. Chemical heating is the release of potential energy from recombining reactive species on the surface to form molecules. For a stable surface interacting with partially-dissociated air, the chemical heating component is due to surface-catalyzed recombination reactions of atomic O and N to produce molecular O2, N2, and NO. Unfortunately, heat flux measurements provide no fundamental information about the surface recombination pathways involved, or how the energy reaches the surface. Rather, they give a total heating rate. This work has taken steps to advance the current poor understanding about the chemical energy transport to and from material surfaces in high-temperature, recombining plasmas. A combination of spatially resolved laser-based diagnostics and emission spectroscopy was used to measure the number densities and gradients of the reactants (N, O), the products (NO, N2) and the energy distribution of recombined molecules (NO, N2) in the boundary layer adjacent to a plasma heated material. Laser excitation can probe individual species by electronic state (atoms) and by electronic, vibrational and rotational states (molecules). Emission can probe the radiative emission for a range of species and electronic, vibrational and rotational states of both atoms and molecules. These measurements of spatial variations in species concentrations through the boundary layer are directly related to near-surface gas-phase chemistry and energy exchange and have provided experimental information that was not currently available. Results provide the initial steps to determine recombination rates and the energy deposited on the surface due to surface catalyzed recombination of atomic nitrogen and oxygen in air plasma.

This dissertation describes the design, synthesis and biological evaluation of novel CDK5/p25 small molecule inhibitors. Cyclin dependent kinase 5 (CDK5) is a proline directed serine/threonine kinase which plays an important role in the pathology of Alzheimer's disease (AD). CDK5/p25 has been implicated in hyperphosphorylation of tau protein which forms neurofibrillary tangles (NFTs), a contributing factor to the pathology of Alzheimer's disease (AD). Based on the deposited X-ray crystal structure of CDK5/p25 with a non-selective CDK inhibitor R-Roscovitine (PDB ID: 1UNL), eight series of novel compounds with a benzimidazole core were designed, synthesized and tested as inhibitors of CDK5/p25. An efficient synthesis of trisubtituted benzimidazoles was developed to explore the SAR at the 1-, 4-, and 6- positions of the benzimidazole core. X-ray crystal structure verification of an intermediate confirmed selective alkylation of the N-1 position of the benzimidazole scaffold. Synthesis of N-1, N-4, C6-O, C6-N, C6-C and C-2 substituted benzimidazoles were achieved via Mitsunobu coupling, Suzuki Miyaura coupling, Buchwald coupling and reductive alkylation strategies. Aminothiazole scaffolds are an established class of CDK inhibitors including CDK5. A molecular hybridization technique was applied to the design of a series of 2-, 5- disubstituted aminothiazoles incorporating structural features of both the Meriolins, natural product CDK inhibitors, and known aminothiazole scaffolds. Synthetic techniques employed included aryl lithiation, deoxygenation and acylation. / Mylan School of Pharmacy and the Graduate School of Pharmaceutical Sciences / Medicinal Chemistry / PhD / Dissertation

This dissertation describes the design, synthesis and biological evaluation of novel CDK5/p25 small molecule inhibitors. Cyclin dependent kinase 5 (CDK5) is a proline directed serine/threonine kinase which plays an important role in the pathology of Alzheimer's disease (AD). CDK5/p25 has been implicated in hyperphosphorylation of tau protein which forms neurofibrillary tangles (NFTs), a contributing factor to the pathology of Alzheimer's disease (AD). Based on the deposited X-ray crystal structure of CDK5/p25 with a non-selective CDK inhibitor R-Roscovitine (PDB ID: 1UNL), eight series of novel compounds with a benzimidazole core were designed, synthesized and tested as inhibitors of CDK5/p25. An efficient synthesis of trisubtituted benzimidazoles was developed to explore the SAR at the 1-, 4-, and 6- positions of the benzimidazole core. X-ray crystal structure verification of an intermediate confirmed selective alkylation of the N-1 position of the benzimidazole scaffold. Synthesis of N-1, N-4, C6-O, C6-N, C6-C and C-2 substituted benzimidazoles were achieved via Mitsunobu coupling, Suzuki Miyaura coupling, Buchwald coupling and reductive alkylation strategies. Aminothiazole scaffolds are an established class of CDK inhibitors including CDK5. A molecular hybridization technique was applied to the design of a series of 2-, 5- disubstituted aminothiazoles incorporating structural features of both the Meriolins, natural product CDK inhibitors, and known aminothiazole scaffolds. Synthetic techniques employed included aryl lithiation, deoxygenation and acylation. / Mylan School of Pharmacy and the Graduate School of Pharmaceutical Sciences; / Medicinal Chemistry / PhD; / Dissertation;

Thesis advisor: Amir H. Hoveyda / Chapter 1. In this chapter, the ability of chiral bidentate N-heterocyclic carbenes (NHCs) to activate alkylmetal reagents directly in order to promote C&#8210;C bond forming reactions in the absence of a Cu salt is presented. Highly regio- and enantioselective Cu-free allylic alkylation reactions of di- and trisubstituted allylic substrates with organomagnesium, organozinc, and organoaluminum reagents are demonstrated. Chiral bidentate sulfonate-bearing NHC-Zn and NHC-Al complexes are isolated and fully characterized. Based on crystal structures of these catalytic complexes, mechanistic details regarding Cu-free allylic alkylations with alkylmetal reagents are proposed. Chapter 2. New methods for efficient and highly enantioselective Cu-catalyzed allylic alkylation reactions of a variety of trisubstituted allylic substrates with alkylmagnesium and alkyl-, aryl-, 2-furyl-, and 2-thiophenylaluminum reagents are presented. Transformations are promoted by a chiral NHC complex in the presence of commercially available, inexpensive and air stable CuCl2*H2O. Enantiomerically enriched compounds containing difficult-to-access all-carbon quaternary stereogenic centers are obtained. Chapter 3. New methods for highly site- and enantioselective Cu-catalyzed allylic alkylation reactions of allylic phosphates with vinylaluminum reagents are presented. The requisite vinylaluminums are prepared by reaction of readily accessible terminal alkynes with DIBAL-H and used directly without further purification. Vinyl additions are promoted in the presence of a chiral bidentate sulfonate-based NHC complex and a Cu salt. The desired SN2' products are obtained in >98% E selectivities, >98% SN2' selectivities, >98% group selectivities (<2% i-Bu addition) and high enantioselectivities. The enantioselective total synthesis of the natural product bakuchiol highlights the versatility of the one-pot hydroalumination/Cu-catalyzed enantioselective allylic vinylation process. Chapter 4. Efficient and highly site-selective Cu-catalyzed hydroboration reactions of 1,2-disubstituted aryl olefins with bis(pinacolato)diboron (B2(pin)2) are presented. Transformations are promoted by an NHC-Cu complex in the presence of MeOH, affording only secondary &#946;-boronate isomers. A Cu-catalyzed method for the synthesis of enantiomerically enriched secondary alkylboronates promoted by chiral NHC complexes is disclosed. Chapter 5. A new method for efficient and site-selective tandem Cu-catalyzed copper-boron additions to terminal alkynes with B2(pin)2 in the presence of an NHC-Cu complex is demonstrated. In a one-pot process, Cu-catalyzed hydroboration of alkynes provides vinylboronates in situ, which undergo a second site-selective hydroboration to afford vicinal diboronates. Highly Enantiomerically enriched diboronates obtained through Cu-catalyzed enantioselective dihydroboration in the presence of chiral bidentate sulfonate-based NHC-Cu complex are obtained. The control of site selectivity in the first-stage hydroboration of alkynes is critical for efficient and highly enantioselective reactions in the tandem dihydroboration. Functionalizations of the vicinal diboronates described herein underline the significance of the current method. / Thesis (PhD) — Boston College, 2010. / Submitted to: Boston College. Graduate School of Arts and Sciences. / Discipline: Chemistry.

This thesis is the use of commercially available methyl 2-iodobenzoate as the starting material and was prepared into iodine - oxazoline compound 118. Then, we undergo copper-catalyzed cross-coupling reactions of compound 118with thiols, and were readily facilitated to afford the corresponding desired products 127¡B136 in good to excellent yields. This method not only modified short- comings of that adding strong base to synthesis of sulfur-oxazoline ligands in past years but also has a good yield performances, the yield is 70 -87%. And we will use this strategy to undergo one pot reaction of carbon-sulfur coupling in future. In the end, we used new sulfur-oxazoline ligands127¡B128 in the Pd-catalyzed asymmetric alkylation of 1,3-diphenyl-2-propenyl acetate with dimethyl malonate. and reaction ee% were high, with the best result of 99% and 93% conversion.

京都大学 / 新制・課程博士 / 博士(薬科学) / 甲第24555号 / 薬科博第172号 / 新制||薬科||19(附属図書館) / 京都大学大学院薬学研究科医薬創成情報科学専攻 / (主査)教授 大野 浩章, 教授 小野 正博, 教授 掛谷 秀昭 / 学位規則第4条第1項該当 / Doctor of Pharmaceutical Sciences / Kyoto University / DFAM

Le cancer de l’ovaire représente la quatrième cause de décès par cancer chez la femme. En France, près de 4 500 nouveaux cas par an sont diagnostiqués, avec plus de 3000 décès chaque année. Ce cancer reste longtemps silencieux : un diagnostic souvent tardif, et le développent d’une chimiorésistance qui touche jusqu'à 75 % des patientes, expliquent le fort taux de mortalité et une survie à 5 ans estimée à moins de 45 %. Les mécanismes responsables du développement de la chimiorésistance sont nombreux. Aujourd’hui, un fort intérêt est porté au développement de nouvelles stratégies de traitement en ciblant les protéines cellulaires inhibitrices de l’apoptose (mort cellulaire programmée). Deux familles de protéines jouent un rôle cruciale dans la régulation de l’apoptose : la famille Bcl-2 et la famille IAP. Nous nous sommes intéressés à la synthèse de petites molécules abiotiques, appelées foldamères. Ces composés sont capables de perturber les interactions entre les protéines anti-apoptotiques des familles Bcl-2 ou IAP, surexprimées dans le cancer de l’ovaire, et leurs partenaires biologiques (pro-apoptotiques). Ceci permet de libérer les protéines pro-apoptotiques et rétablir l’apoptose dans les cellules cancéreuses. Ce travail de thèse a permis la conception, la synthèse, la caractérisation et l’évaluation biologique de molécules inhibitrices des protéines anti-apoptotiques Mcl-1 et Bcl-xL de la famille Bcl-2, et de possibles inhibiteurs de la protéine XIAP de la famille IAP. / Ovarian cancer is the 4th leading cause of cancer death in women. In France, nearly 4,500 new cases per year are diagnosed, with more than 3,000 deaths each year. This cancer remains silent for a long time: late diagnosis and chemoresistance development for up to 75% of patients, explain the high mortality rate and the 5-year survival estimated at less than 45%. Mechanisms responsible for the development of drug resistance are numerous. Today, there is a strong interest in the development of new treatment strategies by targeting cellular proteins that inhibit apoptosis (programmed cell death). Two families of proteins play a crucial role in the regulation of apoptosis: the Bcl-2 family and the IAP family. We are interested in the synthesis of small abiotic molecules, called foldamers. These compounds are able to disrupting the interactions between the anti-apoptotic proteins of the Bcl-2 or IAP families, overexpressed in ovarian cancer, and their biological (pro-apoptotic) partners. This releases the pro-apoptotic proteins and restores apoptosis in the ovarian cancer cells. This PhD work allowed the design, synthesis, characterization and biological evaluation of inhibitors of Mcl-1 and Bcl-xL anti-apoptotic proteins of Bcl-2 family, and the development of possible inhibitors of the XIAP protein of IAP family.

京都大学 / 0048 / 新制・課程博士 / 博士(理学) / 甲第18808号 / 理博第4066号 / 新制||理||1585(附属図書館) / 31759 / 京都大学大学院理学研究科化学専攻 / (主査)教授 丸岡 啓二, 教授 時任 宣博, 教授 大須賀 篤弘 / 学位規則第4条第1項該当 / Doctor of Science / Kyoto University / DGAM

The major directions of this dissertation involve (1) the syntheses and characterization of molecular polygons incorporating sp1hybridized carbon linkers and L2Pt corners (L2 = cis-1,3-diphosphine), (2) the development of protected carbon chain complexes featuring fluorous phosphine ligands and (3) click reactions of metal terminal polyynyl complexes and further metallations of the resulting triazole rings. A brief overview is provided in Chapter I. Chapter II details the syntheses of molecular squares containing bidendate diphosphine ligands of the formula R2C(CH2PPh2)2 where R = Me, Et, n-Bu, n-Dec, Bn, and p-tolCH2 (general designation dppp*), in which the R2 groups are intended to circumvent the solubility issues encountered by others. Their syntheses involve double substitutions of the dimesylate compounds R2C(CH2OMs)2 using KPPh2. Building blocks of the formulae (dppp*)PtCl2 and (dppp*)Pt((C≡C)2H)2 are synthesized and characterized, including one crystal structure of the latter. The target complexes are accessed by reactions of (dppp*)PtCl2 with (dppp*)Pt((C≡C)2H)2 under Sonogashira type conditions. Six new squares of the formula [(R2C(CH2PPh2)2)Pt(C≡C)2]4 are characterized including two crystal structures. Further topics include approaches to higher homologues and cyclocarbon synthesis. Chapter III focuses on carbon chain complexes bearing fluorous phosphine ligands of the formula P((CH2)mRfn)3 (Rfn = (CF2)n-1CF3; m/n = 2/8, 3/8, and 3/10). Precursors of the formula trans-(C6F5)((Rfn(CH2)m)3P)2PtCl are synthesized and characterized, including one crystal structure, which reveals phase separation of the fluorous and non-fluorous domains. Reactions with butadiyne give trans-(C6F5)((Rfn(CH2)m)3P)2Pt(C≡C)2H. Oxidative homocouplings afford the target complexes trans,trans-(C6F5)((Rfn(CH2)m)3P)2Pt(C≡C)4(C6F5)(P((CH2)mRfn)3)2Pt. Cyclic voltammetry indicates irreversible oxidations of the title compounds, in contrast to partially reversible oxidations of non-fluorous analogues. Chapter IV focuses on multimetallic complexes achieved by click reactions in metal coordination spheres. The copper catalyzed click reaction between trans-(C6F5)(p-tol3P)2Pt(C≡C)2H (1) and (η5-C5H4N3)Re(CO)3 affords the bimetallic 1,2,3-triazole trans-C6F5)(p1tol3P)2PtC≡CC=CHN((η51C5H4)Re(CO)3)N=N. Further reactions with Re(CO)5OTf and Re(CO)5Br give trimetallated adducts, which represent the first species of this type. An alternative route to a trimetallic complex involves the twofold cycloaddition of the diazide (η5-C5H4N3)2Fe and 1, giving (η5-C5H4NN=N-C(trans-(C≡C)Pt(Pp-tol3)2(C6F5)=CH)2Fe. The crystal structures of the di and trimetallic complexes are compared, but attempts to achieve a fourth metallation involving the =CH groups are unsuccessful. However, when the triazolium salt [trans-(C6F5)(p-tol3P)2PtC≡CC=CHN(CH2C6H5)N=N(Me)]+ I– is treated with Ag2O and [Rh(COD)Cl]2, a =CRh adduct is obtained. The success of =CH metallation is correlated to the 1H NMR chemical shift, indicative of an electronic effect.

Les récepteurs de l'adrénomédulline sont fortement exprimés dans les capillaires alvéolaires humains et fournissent une cible moléculaire pour l'imagerie de la circulation et de l'embolie pulmonaire. Au cours des années précédentes, le dérivé DFH12 marqué au 99mTc (PulmoBind) a démontré son potentiel en tant qu'agent d'imagerie SPECT de l'hypertension pulmonaire dans des études cliniques de phase I et II. L’objectif principal de mon projet est de développer le nouvel analogue DFH17 pour l’imagerie TEP des récepteurs de l'adrénomédulline via la méthode de l’Al18F. Pour atteindre cet objectif, un système d’élution semi-automatique a été conçu pour produire l’Al18F concentré directement dans le vial de réaction. En utilisant des tests de complexation avec le chélateur NOTA, des conditions optimales ont été trouvées pour le radiomarquage du DFH17 avec l’Al18F. La combinaison du rapport Al/DFH17 1:3 dans l'éthanol 50% a permis de produire le [18F]AlF-DFH17 avec des puretés radiochimiques et chimiques élevées. Les études TEP avec le [18F]AlF-DFH17 ont démontré un rapport élevé poumon-bruit de fond ainsi qu’une grande stabilité in vivo chez le rat, le chien et le primate. Des captations différenciées dans les poumons des trois espèces ont aussi été détectées par imagerie TEP et leurs différences ont été associées à des variations de la composant RAMP2. Compte tenu de l’importante captation pulmonaire, de la stabilité in vivo et de la dosimétrie favorable, le nouveau dérivé [18F]AlF-DFH17 est un excellent candidat potentiel en tant que traceur TEP des récepteurs adrénomédulline humains. L’expression des récepteurs AT1 de l’angiotensine II est altérée dans plusieurs maladies cardiovasculaires et rénales, telles la défaillance cardiaque, rénale et l’hypertension ainsi que dans certains cancers. Auparavant, le dérivé [11C]méthyl-Candesartan a démontré un potentiel comme agent d'imagerie TEP de l'AT1R rénal mais une proportion élevée du signal TEP correspondait à une liaison non-spécifique d'un radiométabolite hydrophobe. Dans ce travail, l’objectif principal est de développer le nouveau dérivé [18F]fluorobenzyl-Candesartan en utilisant le 4[18F]fluoroiodobenzène ([18F]FIB) avec un profil métabolique et de biodistribution potentiellement meilleurs. Pour atteindre cet objectif, des paramètres réactionnels de fluorination tels que le solvant, la quantité de précurseur, le catalyseur et la température ont été optimisés permettant la radiosynthèse du [18F]FIB avec des rendements et pureté élevés. Ensuite, le couplage du [18F]FIB au dérivé alcyne-trityl-Candesartan a été évalué en utilisant la réaction de Sonogashira suivie d'une détritylation acide. Suite à l’étude de plusieurs conditions de couplage, le rendement de radioconversion a été légèrement augmenté en utilisant le catalyseur Pd(PPh3)4/CuI et K2CO3 comme base. Les meilleures conditions de fluorination et de couplage ont été automatisées pour le module de synthèse Synthra® RNPlus Research. La production du [18F]FB-Candesartan été atteinte avec de faibles rendements et activités molaires en raison de la formation d’impuretés ayant des structures et temps de rétention par HPLC similaires à ceux de notre traceur. Des études supplémentaires afin d'améliorer le rendement, la purification par HPLC et l'activité molaire se sont avérées infructueuses pour l’instant. D’autres expériences devront être effectuées à cette fin. En conclusion, l'utilisation de la réaction de Sonogashira pour produire le [18F]FB-Candersartan avec des rendements et des activités molaires élevées s'est avérée difficile. / Adrenomedullin receptors are highly expressed in human alveolar capillaries and provide a molecular target for imaging the integrity of pulmonary microcirculation. In previous years, the 99mTc-labeled DFH12 derivative (PulmoBind) demonstrated its potential as a SPECT imaging agent of pulmonary hypertension in phase I and II clinical trials. In this work, we aimed to develop a NOTA-derivatized adrenomedullin analog (DFH17), radiolabeled with aluminum fluoride ([18F]AlF), for PET imaging of pulmonary microcirculation. To achieve this goal, highly concentrated [18F](AlF)2+ was produced from purified 18F using a semi-automatic system. Using inexpensive complexation assays with NOTA, optimal conditions at each step of the process were determined facilitating the radiolabeling optimization of DFH17. Furthermore, combining the Al-to-DFH17 1:3 ratio in 50% ethanol as co-solvent, allowed [18F]AlF-DFH17 production in high radiochemical and chemical purities. PET/CT and biodistribution demonstrated high [18F]AlF-DFH17 lung-to-background ratio and in vivo stability in rats, dog and primate. Contrasted inter-species uptake in the lungs associated with variations of RAMP2 were also detected by PET imaging. Considering high lung uptake, in vivo stability and favorable dosimetry observed in the monkey, the novel AM derivative [18F]AlF-DFH17 exhibits an excellent potential as a PET tracer of human AM receptors. Alterations of the expression levels of AT1R has been linked to cardiac and renal diseases, such as cardiac and renal failures, hypertension and some type of cancers. Previously, [11C]methyl-Candesartan displayed potential for PET imaging of AT1Rs, but a high proportion of PET signal corresponded to non-specific binding from a 11C-labeled hydrophobic metabolite. In this work, the main objective was to develop the novel derivative [18F]fluorobenzyl-Candesartan, with potentially better metabolic profile and biodistribution, using 4-[18F]fluoroidobenzene ([18F]FIB) as prosthetic group. To pursue this goal, radiofluorination parameters such as solvent, amount of precursor, type of catalyst and temperature were optimized to reliably synthesize [18F]FIB in high yield and purity. Coupling of [18F]FIB to the alkyne-trityl-Candesartan was evaluated using the Sonogashira cross-coupling reaction followed by an acid deprotection. After studying several Pd-cross-coupling conditions, the radioconversion yield was slightly increased by means of a Pd(PPh3)4/CuI catalyst and K2CO3 as base in DMF. Therefore, the best reaction conditions for [18F]FIB fluorination and its coupling to alkyne-Candesartan followed by an acid hydrolysis, was fully automated for Synthra® RNPlus Research synthesis module. In general, the synthesis of [18F]FB-Candesartan was achieved in low yields and molar activities due to the formation of structurally-close by-product(s) with similar HPLC retention time. Additional studies to further improve the yield, HPLC purification and molar activity (MA) have been unsuccessful. Other experiments will need to be performed to this end. In conclusion, the use of Sonogashira cross-coupling reaction to produce [18F]FB-Candesartan in high yields and molar activities was found to be challenging.